Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and ...

Merck & Co., Inc. (NYSE:MRK) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company shared encouraging results from its Phase 3 HYPERION trial.

Merck & Co., Inc. (NYSE:MRK) is a leading pharmaceutical company, best known for its strong presence in oncology, ...

A free pet wellness clinic offering vaccines and microchips will be held June 28 in East Cleveland for Cleveland and East ...

Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

In the latest trading session, Merck (MRK) closed at $78.83, marking a -1.05% move from the previous day. This change lagged the S&P 500's 0.8% gain on the day. Meanwhile, the Dow gained 0.94%, and ...

A new slate of vaccine advisers to the US Centers for Disease Control and Prevention voted Thursday to recommend that ...

The votes on vaccine recommendations are the first move by the panel after Health and Human Services Secretary Robert F.

The vote offers a sigh of relief to doctors and public health experts worried about vaccine skepticism creeping into policymaking.